NPY1R-targeted peptide-mediated delivery of a dual PPARα/γ agonist to adipocytes enhances adipogenesis and prevents diabetes progression

• Váldodahkkit: Stefanie Wittrisch (Dahkki), Nora Klöting (Dahkki), Karin Mörl (Dahkki), Rima Chakaroun (Dahkki), Matthias Blüher (Dahkki), Annette G. Beck-Sickinger (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Elsevier, 2020-01-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Objective: PPARα/γ dual agonists have been in clinical development for the treatment of metabolic diseases including type 2 diabetes and dyslipidemia. However, severe adverse side effects led to complications in clinical trials. As most of the beneficial effects rely on the compound activity in adip...